Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Beck

Showing results (201-210 of 233) with videos related to

Pageof 24
Sort By:
Genetics in Medicine : Official Journal of the American College of Medical Genetics|May 18, 2013
Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfaRaphael Schiffmann, Markus Ries, Derek Blankenship, et al.
Laryngo- Rhino- Otologie|July 23, 2021
[Therapies for synchronous malignomas - the importance of interdisciplinary oncology]Sarina Müller, Marlen Haderlein, Maximilian Traxdorf, et al.
Molecular and Cellular Biochemistry|April 22, 2022
Hepatocyte expressed chemerin-156 does not protect from experimental non-alcoholic steatohepatitisRebekka Pohl, Laura Eichelberger, Susanne Feder, et al.
Orphanet Journal of Rare Diseases|June 20, 2022
Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registryMichael Beck, Uma Ramaswami, Elizabeth Hernberg-Ståhl, et al.
The Journal of Pediatrics|May 6, 2004
Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase)James E Wraith, Lorne A Clarke, Michael Beck, et al.
Orphanet Journal of Rare Diseases|May 4, 2017
Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registryJoseph Muenzer, Simon A Jones, Anna Tylki-Szymańska, et al.
American Journal of Medical Genetics. Part A|February 4, 2005
Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)Stuart J Swiedler, Michael Beck, Manal Bajbouj, et al.
Orphanet Journal of Rare Diseases|September 28, 2013
Functional and genetic characterization of the non-lysosomal glucosylceramidase 2 as a modifier for Gaucher diseaseYildiz Yildiz, Per Hoffmann, Stefan Vom Dahl, et al.
Contact Dermatitis|August 8, 2007
Dicaprylyl maleate--an emerging cosmetic allergenHelen Lotery, Stephen Kirk, Michael Beck, et al.
Molecular Genetics and Metabolism|December 3, 2009
A validated disease severity scoring system for Fabry diseaseEdward H Giannini, Atul B Mehta, Max J Hilz, et al.
Pageof 24

Showing results (201-210 of 233) with videos related to

Sort By:
Pageof 24
Genetics in Medicine : Official Journal of the American College of Medical Genetics|May 18, 2013
Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfaRaphael Schiffmann, Markus Ries, Derek Blankenship, et al.
Laryngo- Rhino- Otologie|July 23, 2021
[Therapies for synchronous malignomas - the importance of interdisciplinary oncology]Sarina Müller, Marlen Haderlein, Maximilian Traxdorf, et al.
Molecular and Cellular Biochemistry|April 22, 2022
Hepatocyte expressed chemerin-156 does not protect from experimental non-alcoholic steatohepatitisRebekka Pohl, Laura Eichelberger, Susanne Feder, et al.
Orphanet Journal of Rare Diseases|June 20, 2022
Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registryMichael Beck, Uma Ramaswami, Elizabeth Hernberg-Ståhl, et al.
The Journal of Pediatrics|May 6, 2004
Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase)James E Wraith, Lorne A Clarke, Michael Beck, et al.
Orphanet Journal of Rare Diseases|May 4, 2017
Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registryJoseph Muenzer, Simon A Jones, Anna Tylki-Szymańska, et al.
American Journal of Medical Genetics. Part A|February 4, 2005
Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)Stuart J Swiedler, Michael Beck, Manal Bajbouj, et al.
Orphanet Journal of Rare Diseases|September 28, 2013
Functional and genetic characterization of the non-lysosomal glucosylceramidase 2 as a modifier for Gaucher diseaseYildiz Yildiz, Per Hoffmann, Stefan Vom Dahl, et al.
Contact Dermatitis|August 8, 2007
Dicaprylyl maleate--an emerging cosmetic allergenHelen Lotery, Stephen Kirk, Michael Beck, et al.
Molecular Genetics and Metabolism|December 3, 2009
A validated disease severity scoring system for Fabry diseaseEdward H Giannini, Atul B Mehta, Max J Hilz, et al.
Pageof 24